Published in December 15th, 2009
Advertisements
The biotech and pharmaceutical industries face new changes with proposed rules concerning cGMP (current good manufacturing practice) for combination products. The cGMP proposal (74 Fed. Reg. 48,423) by the FDA’s Office of Combination Products (OCP) won’t create brand-new requirements. However, this proposed rule clarifies confusion applied to devices, drugs and biological products that are used to create combination products. Pharmaceutical consulting firms state that 300 manufacturers will be affected by this new regulation proposal.
What Defines a Combination Product?
A combination product is a product combined with two or more FDA components. FDA regulates drugs and devices under FDCA (Federal Food, Drug, and Cosmetic Act). Biological products are placed under section 351 of PHS Act (Public Health Service Act). HCT/Ps are found under section 361 of the PHS Act.
These FDA regulated components include the following:
• Drugs
• Biologics (i.e. blood/blood components)
• Medical devices
• Human cell or tissue products (also known as “HCT/Ps”)
Combination products are described as:
• Physically combined during manufacturing – reates single entities or two separate component in the same package – also known as “co-packaging”
• Cross labeled – Components are manufactured separately and packaged (but labeled specifically for use with another product)
Clarification of cGMP Requirements
According to the FDA, each product has separate cGMP regulations. When products are combined together, confusion occurs as to which regulations apply to products when they are combined.
These new OCP regulations concerning combination products would clarify the following issues:
• Reduce confusion regarding cGMP requirements applied to combination products
• Ensure consistency with applications and enforce necessary requirements
The biggest issue with combination products is when constituents are combined in co-packaging or single entities. Overall, these revised regulations streamline options – avoids establishing duplicate drug and device quality systems.
The FDA reports that compliance with these cGMP regulations would not add extra burdens on manufacturers, and would actually reduce the paperwork hassle associated with co-packaged and single-entity combination products.
In 2004, the OCP issued draft guidance but never finalized it. Instead of finalizing the original draft guidance, the OCP decided to write new regulations that are similar to the proposed draft guidance.
The FDA plans to follow necessary administrative processes. They will finalize comments by the end of December 2009, and make these new regulations effective 180 days from its publication date. These new rules will ease the confusing issues that both the pharmaceutical and biotech industries have concerning combination products.
Sample Sections of Proposed Regulations
• Sec 4.3. – Identifies drug cGMP regulations which applies to drug constituents of combination products. (i.e. QSR for devices). It also applies cGMP regulations of constituent parts for combination products created by cross labeling.
• Sec 4.4. – FDA states that constituent parts of combination products retain regulatory stats (drugs or devices), even after parts are combined. Also, cGMP requirements continue to apply to each constituent part – whether they are in a co-packaged product or physically combined in single entities. The manufacturer adheres to cGMPs for drug constituents and QSR for device constituents.
If you liked this article, tell all your friends about it. They’ll thank you for it. If you have a blog or website, you can link to it or even post it to your own site (don’t forget to mention www.smartconsultinggroup.com as the original source).
nigel smart is a http://www.smartconsultinggroup.com/pharmaceutical-consulting.htmlpharmaceutical consulting with extensive experience in the biotechnology and pharmaceutical industry. with denise smart, he manages smart consulting group. visit their blog at www.smartconsultinggroup.com/blog
Related posts:
- FDA Resolves Compliance Issues With Drug/Device Combination ... Drug/device combination products raise compliance and regulatory issues in the pharmaceutical industry. On their own, each drug and device has their own specific type of marketing and good manufacturing practices regulation. However, when drugs and devices are combined together, they pose a new compliance question – how will this new combined product be regulated as [...]...
- FDA Approval For Natural Cures: Don’t Hold Your Breath It’s funny when you pick up any bottle containing a natural herb or supplement and read the little message at the bottom: “These statements have not been evaluated by the Food and Drug Administration.” Ever wonder when the FDA is going to get around to evaluating them? After all, they have only been used for [...]...
- Pharmaceutical Industry Contributes to Future of ... Pharmaceutical and biotech companies are turning to the future of personalized medicine – the personalized treatment and diagnosis of disease. In the past, a “one size fits all” approach to medicine hasn’t been the best solution. Scientific research didn’t take into account the influence of genes on an individual’s health and well-being. Personalized medicine has [...]...
- Pharmaceutical Companies Rush Ahead to Prepare Swine Flu ... Because of the recent Swine Flu virus that has swept the globe, many drug manufacturers are doing whatever they can to produce ample amounts of the vaccine for this upcoming flu season, but they are having more problems than anticipated. Many pharmaceutical companies are having trouble growing enough of the swine flu virus to produce [...]...
- FDA Bans Drugs Containing Ephedra Due to Health Risks Ephedra is a naturally occurring substance derived from the Asian supplement Ma Huang and is also known as Ephedrine, Pseudoephedrine, and Epitonin. Its principal active ingredient is Ephedrine, a drug that is regulated by the Food and Drug Administration (FDA) and found in over-the-counter asthma medications. While products containing natural Ephedrine alkaloids have long been [...]...
- Manufacturers of Type 2 Diabetes Prescription Drug Receive ... GlaxoSmithKline, makers of the type 2 diabetes prescription drug known as Avandia, recently received warnings from the U.S. Food and Drug Administration (FDA) after the company withheld post-marketing research information on Avandia. Avandia, also known as its generic name rosiglitazone maleate, is an oral medication used to control an individual’s blood sugar level as well [...]...
- Fluoroquinolones Receive Black Box Label By FDA A group of antibacterial prescription drugs has recently been subject to a warning label increase by the U.S. Food and Drug Administration (FDA). The fluoroquinolone group consists of several various types of antibiotics that treat an array of bacterial infections. The drug types within the fluoroquinolone family include: * Levaquin (levofloxacin) * Factive (gemifloxacin mesylate) [...]...
- Treating Nail Fungus – 3 Type of Oral Pharmaceutical ... You have tried everything on your nail fungus: OTC antifungal ointments and creams, Penlac, Vicks Vaporub, Listerine, tea tree oil, vinegar. You have used them individually and in combinations as recommended by friends, all to no avail. You have other recourse but to try oral medication. Nail fungus is scientifically known as onychomycosis. It is [...]...
- FDA Says Dental Fillings Are Toxic – Now Will You ... The FDA, the world’s major health regulator announced on 5th June 2008, something thousands of us have known for years, – dental amalgam fillings are toxic. Amalgam means a mixture of mercury and another metal (or metals). In the early 1800′s it was originally developed as a cheaper alternative to gold, and consisted of a [...]...
- Pharmaceutical Grading Of Ginkgo Biloba – Ginko Biloba ... Before we go any further is important the terms pharmaceutical grade should be made clear then only can Pharmaceutical Grading Of Ginkgo Biloba be understood. The process of deriving botanical supplies (used in patient treatment dr paul is a md who provides online resources on http://www.myginkgobiloba.com/benefits-of-ginkgo-biloba.phpginkgo biloba benefits as well as papers on how http://www.myginkgobiloba.com/ginkgo-biloba-can-help-tinnitus.phpginkgo [...]...
Previous post:
«
Improve Your Health Before Aging External and InternalNext post: Everything You Need To Know About Cosmetic Dentistry »